Chronic atrophic gastritis: focus on diagnosis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, chronic atrophic gastritis is a risk factor for the development of gastric cancer. Data on the prevalence of chronic atrophic gastritis in Russia and the world are limited. Among the adult population of St. Petersburg aged 21 to 81 years, the prevalence of histologically verified chronic atrophic gastritis is 5.3%. Moreover, the chances of developing chronic atrophic gastritis in people over the age of 60 years compared to the group of 45–59 years are 2.5 times higher (95% confidence interval 1.5–4.1).

Morphological verification of the Operative Link for Gastritis Assessment diagnosis is not carried out in clinical practice in most cases. However, this method remains the most reliable method for timely verification of chronic atrophic gastritis, including chronic atrophic gastritis of mixed origin (autoimmune gastritis and Helicobacter pylori-associated gastritis), especially in the case of a seronegative variant of autoimmune gastritis.

Also, in addition to the heterogeneity of epidemiological data on chronic atrophic gastritis, there is disagreement about how to confirm its etiology as well as about the correlation of serological markers of atrophy and histological stage.

Full Text

Restricted Access

About the authors

Igor G. Bakulin

North-Western State Medical University named after I.I. Mechnikov

Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021
SPIN-code: 5283-2032

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Anastasiia G. Sushilova

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: anastasiya.s1311@gmail.com
ORCID iD: 0000-0002-7277-5046
SPIN-code: 4026-5160

MD, postgraduate student

Russian Federation, Saint Petersburg

Alexander V. Zharkov

North-Western State Medical University named after I.I. Mechnikov; Healthcare Committee of the Leningrad Region

Email: al.zharkov@bk.ru
ORCID iD: 0000-0001-6649-0928

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg; Saint Petersburg

References

  1. Bakulin IG, Sushilova AG, Zharkov AV. The effectiveness of including screening for chronic atrophic gastritis and Helicobacter pylori infection in clinical examination programs. Therapy. 2023;9(7):8–14. (In Russ.) doi: 10.18565/therapy.2023.7.8-14
  2. Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology. 2021;161(4):1325–1332.e7. doi: 10.1053/j.gastro.2021.06.078
  3. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi: 10.1136/gutjnl-2015-309252
  4. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021. doi: 10.1002/ijc.33588
  5. Kaprin AD, Starinsky VV, Shakhzadova AO. The state of oncological care for the population of Russia in 2020. Moscow; 2021. 239 p. Available from: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf. Accessed: 11.09.2023. (In Russ.)
  6. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745
  7. Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United Eur Gastroenterol J. 2018;6(2):192–202. doi: 10.1177/2050640617722902
  8. Carabotti M, Annibale B, Lahner E. Common pitfalls in the management of patients with micronutrient deficiency: keep in mind the stomach. Nutrients. 2021;13(1):208. doi: 10.3390/nu13010208
  9. Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primer. 2020;6(1):56. doi: 10.1038/s41572-020-0187-8
  10. Park JY, Cornish TC, Lam-Himlin D, et al. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting. Am J Surg Pathol. 2010;34(11):1591–1598. doi: 10.1097/PAS.0b013e3181f623af
  11. Bakulina N, Tikhonov S, Malkov V, et al. Non-invasive screening of autoimmune atrophic gastritis in asymptomatic subjects by Serological Biomarker Test (GastroPanel®). Anticancer Res. 2022;42(3):1517–1526. doi: 10.21873/anticanres.15624
  12. Zhang H, Jin Z, Cui R, et al. Autoimmune metaplastic atrophic gastritis in chinese: a study of 320 patients at a large tertiary medical center. Scand J Gastroenterol. 2017;52(2):150–156. doi: 10.1080/00365521.2016.1236397
  13. Notsu T, Adachi K, Mishiro T, et al. Prevalence of autoimmune gastritis in individuals undergoing medical checkups in Japan. Intern Med Tokyo Jpn. 2019;58(13):1817–1823. doi: 10.2169/internalmedicine.2292-18
  14. Massironi S, Zilli A, Elvevi A, Invernizzi P. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmun Rev. 2019;18(3):215–222. doi: 10.1016/j.autrev.2018.08.011
  15. Tsukanov VV, Tret’yakova OV, Amelchugova OS, et al. The prevalence of atrophic gastritis of the body of stomach at Krasnoyarsk population over 45 years old. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(4):27–31. (In Russ.)
  16. Bakulin IG, Sushilova AG, Serkova MYu. The role of non-invasive screening in assessing the burden of chronic atrophic gastritis. Preventive medicine. 2023;26(5-2):59. (In Russ.)
  17. Haziri A, Juniku-Shkololli A, Gashi Z, et al. Helicobacter pylori infection and precancerous lesions of the stomach. Med Arh. 2010;64(4):248–249.
  18. Chen S, Ying L, Kong M, et al. The Prevalence of Нelicobacter pylori infection decreases with older age in atrophic gastritis. Gastroenterol Res Pract. 2013;2013:494783. doi: 10.1155/2013/494783
  19. Roman LD, Lukyanchuk R, Sablin OA, et al. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel®) in St. Petersburg. Anticancer Res. 2016;36(8):4129–4138.
  20. Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in Russia: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. doi: 10.1111/hel.12924
  21. Bakulina NV, Simanenkov VI, Bakulin IG, Ilchishina TA. Prevalence of Нelicobacter pylori infection among physicians. Experimental and Clinical Gastroenterology. 2017;(12):20–24. (In Russ.)
  22. Zaharova NV, Simanenkov VI, Bakulin IG, et al. Prevalence of Нelicobacter pylori infection in gastroenterological patients in Saint Petersburg. Pharmateka. 2016;(5S):33–39. (In Russ.)
  23. Price AB. The Sydney system: histological division. J Gastroenterol Hepatol. 1991;6(3):209–222. doi: 10.1111/j.1440-1746.1991.tb01468.x
  24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–1181. doi: 10.1097/00000478-199610000-00001
  25. Rugge M, de Boni M, Pennelli G, et al. OLGA can guard the barn. Am J Gastroenterol. 2009;104(12):3099. doi: 10.1038/ajg.2009.512
  26. Rugge M, Fassan M, Pizzi M, et al. Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol. 2011;42(10):1539–1544. doi: 10.1016/j.humpath.2010.12.017
  27. Orgler E, Dabsch S, Malfertheiner P, Schulz C. Autoimmune gastritis: update and new perspectives in therapeutic management. Curr Treat Options Gastroenterol. 2023;21(1):64–77. doi: 10.1007/s11938-023-00406-4
  28. Livzan MA, Gaus OV, Mozgovoi SI, Bordin DS. Chronic autoimmune gastritis: modern diagnostic principles. Diagnostics. 2021;11(11):2113. doi: 10.3390/diagnostics11112113
  29. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–388. doi: 10.1055/a-0859-1883
  30. Vaiphei K. Interpretation of endoscopic biopsy. In: Interpretation of Endoscopic Biopsy — Gastritis, Gastropathies and Beyond. Springer; 2022. P. 19–29. doi: 10.1007/978-981-16-6026-9_4
  31. Livzan MA, Krolevets TS, Mozgovoy SI, et al. Autoimmune gastritis: from symptom to diagnosis. Clinical observations. Consilium Medicum. 2020;22(8):78–84. (In Russ.)
  32. Coati I, Fassan M, Farinati F, et al. Autoimmune gastritis: Pathologist’s viewpoint. World J Gastroenterol. 2015;21(42):12179–12189. doi: 10.3748/wjg.v21.i42.12179
  33. Maev IV, Zajrat’yanc OV, Kucheryavyj YuA. Kishechnaya metaplaziya slizistoj obolochki zheludka v praktike gastroenterologa: sovremennyj vzglyad na problemu. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(4):38–48. (In Russ.)
  34. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54(6):764–768. doi: 10.1136/gut.2004.055400
  35. Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657–667. doi: 10.1111/apt.14248
  36. Koivurova OP, Koskela R, Blomster T, et al. Serological biomarker panel in diagnosis of atrophic gastritis and Нelicobacter pylori infection in gastroscopy referral patients: Clinical Validation of the New-Generation GastroPanel® Test. Anticancer Res. 2021;41(11):5527–5537. doi: 10.21873/anticanres.15366
  37. Kurilovich SA, Belkovec AV, Reshetnikov OV, et al. Prognostic value of the atrophia markers in gastric cancer risk at the west Siberia population (prospective “case-control study”). Experimental and Clinical Gastroenterology. 2017;147(11):13–21. (In Russ.)
  38. Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci. 2011;56(2):145–150. doi: 10.2478/v10039-011-0040-0
  39. Hall SN, Appelman HD. Autoimmune gastritis. Arch Pathol Lab Med. 2019;143(11):1327–1331. doi: 10.5858/arpa.2019-0345-RA
  40. Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20(6):1438–1449. doi: 10.3748/wjg.v20.i6.1438
  41. Best LM, Takwoingi Y, Siddique S, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2
  42. Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015;3(1):9. doi: 10.3978/j.issn.2305-5839.2014.12.04
  43. Gong RJ, Xu CX, Li H, Liu XM. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases. 2021;9(1):133–147. doi: 10.12998/wjcc.v9.i1.133
  44. Shimoyama T, Oyama T, Matsuzaka M, et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey. Helicobacter. 2009;14(2):87–90. doi: 10.1111/j.1523-5378.2009.00672.x
  45. Cardos AI, Maghiar A, Zaha DC, et al. Evolution of diagnostic methods for Нelicobacter pylori infections: From traditional tests to high technology, advanced sensitivity and discrimination tools. Diagn Basel Switz. 2022;12(2):508. doi: 10.3390/diagnostics12020508
  46. Chmiela M, Gonciarz W. Molecular mimicry in Helicobacter pylori infections. World J Gastroenterol. 2017;23(22):3964–3977. doi: 10.3748/wjg.v23.i22.3964
  47. Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.) doi: 10.22416/1382-4376-2021-31-4-70-99

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies